REG - AstraZeneca PLC - Result of AGM

AstraZenecaAnnouncement

Today 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260409:nRSI8855Za&default-theme=true

RNS Number : 8855Z  AstraZeneca PLC  09 April 2026

9 April 2026

Results of Annual General Meeting held on 9 April 2026

AstraZeneca PLC announced the results of the voting at its Annual General
Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were
decided by poll vote. Resolutions 10 - 13 were passed as special resolutions;
all other resolutions were passed as ordinary resolutions.

 

     Resolution                                                                      Votes for      % of votes cast  Votes against  % of votes cast  Votes cast in total  Total votes cast as a % of issued share capital  Votes withheld
 1   To receive the Company's Accounts, the Reports of the Directors and Auditor     1,198,663,815  99.99%           166,701        0.01%            1,198,830,516        77.29%                                           2,309,793
     and the Strategic Report for the year ended 31 December 2025
 2   To confirm the 2025 interim dividends                                           1,199,596,253  99.91%           1,054,621      0.09%            1,200,650,874        77.41%                                           489,438
 3   To appoint KPMG LLP as Auditor                                                  1,200,331,533  99.98%           203,239        0.02%            1,200,534,772        77.40%                                           605,649
 4   To authorise the Directors to agree the remuneration of the Auditor             1,200,231,237  99.98%           277,426        0.02%            1,200,508,663        77.40%                                           631,646
 5a  To re-elect Michel Demaré as a Director                                         1,181,183,631  98.39%           19,312,258     1.61%            1,200,495,889        77.40%                                           644,420
 5b  To re-elect Pascal Soriot as a Director                                         1,188,466,505  99.00%           12,056,196     1.00%            1,200,522,701        77.40%                                           617,611
 5c  To re-elect Aradhana Sarin as a Director                                        1,191,427,943  99.30%           8,391,362      0.70%            1,199,819,305        77.36%                                           1,321,004
 5d  To re-elect Philip Broadley as a Director                                       1,171,470,116  97.59%           28,983,447     2.41%            1,200,453,563        77.40%                                           686,746
 5e  To re-elect Euan Ashley as a Director                                           1,197,441,098  99.75%           3,022,489      0.25%            1,200,463,587        77.40%                                           676,722
 5f  To re-elect Birgit Conix as a Director                                          1,200,028,460  99.96%           428,931        0.04%            1,200,457,391        77.40%                                           683,030
 5g  To re-elect Rene Haas as a Director                                             1,176,085,879  97.97%           24,361,879     2.03%            1,200,447,758        77.40%                                           692,663
 5h  To re-elect Karen Knudsen as a Director                                         1,200,091,469  99.97%           370,843        0.03%            1,200,462,312        77.40%                                           678,109
 5i  To re-elect Diana Layfield as a Director                                        1,199,711,377  99.94%           755,622        0.06%            1,200,466,999        77.40%                                           673,422
 5j  To re-elect Anna Manz as a Director                                             1,199,171,542  99.89%           1,310,287      0.11%            1,200,481,829        77.40%                                           658,592
 5k  To re-elect Sheri McCoy as a Director                                           1,181,129,650  98.39%           19,334,808     1.61%            1,200,464,458        77.40%                                           675,963
 5l  To re-elect Tony Mok as a Director                                              1,197,756,109  99.77%           2,702,422      0.23%            1,200,458,531        77.40%                                           681,890
 5m  To re-elect Marcus Wallenberg as a Director                                     993,713,162    83.80%           192,121,282    16.20%           1,185,834,444        76.46%                                           15,305,980
 6   To approve the annual statement of the Chair of the Remuneration Committee and  1,161,885,452  96.78%           38,608,771     3.22%            1,200,494,223        77.40%                                           646,086
     the Annual Report on Remuneration for the year ended 31 December 2025
 7   To renew the authorisation to grant awards under the French Appendix 3 of the   1,186,833,063  98.89%           13,376,194     1.11%            1,200,209,257        77.38%                                           930,948
     AstraZeneca Performance Share Plan 2020
 8   To authorise limited political donations                                        1,176,818,096  98.50%           17,954,803     1.50%            1,194,772,899        77.03%                                           6,367,525
 9   To authorise the Directors to allot shares                                      1,115,450,202  92.92%           84,989,076     7.08%            1,200,439,278        77.40%                                           701,146
 10  To authorise the Directors to disapply pre-emption rights                       1,113,184,536  92.75%           87,024,695     7.25%            1,200,209,231        77.38%                                           930,073
 11  To authorise the Directors to further disapply pre-emption rights for           1,053,612,673  87.78%           146,670,037    12.22%           1,200,282,710        77.39%                                           856,594
     acquisitions and specified capital investments
 12  To authorise the Company to purchase its own shares                             1,197,748,658  99.81%           2,335,330      0.19%            1,200,083,988        77.38%                                           1,056,436
 13  To reduce the notice period for general meetings                                1,108,104,727  92.31%           92,307,790     7.69%            1,200,412,517        77.40%                                           727,904

 

Nazneen Rahman retired from the Board at the conclusion of the AGM. For the
purposes of section 430(2B) of the Companies Act 2006, she will receive her
pro-rata entitlement to non-executive director fees for the month of April
2026. No other remuneration payment or payment for loss of office will be
made.

A copy of the resolutions passed at the AGM (other than resolutions concerning
ordinary business) has been submitted to the National Storage Mechanism for
publication, and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Issued capital

As at 7 April 2026, the number of issued shares of the Company was
1,550,988,781 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against all of the resolutions at the
AGM. In accordance with the Company's Articles of Association, on a poll every
member present in person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUPUWACUPQGAB



            Copyright 2019 Regulatory News Service, all rights reserved